Palisade Bio Reports First Quarter 2024 Financial Results and Provides Business Update
May 14, 2024 08:05 ET
|
Palisade Bio, Inc.
– Company on track to commence Phase 1 human clinical study of lead product candidate, PALI-2108, for the treatment of Ulcerative Colitis (UC) before year end – Sufficient cash on hand to...
Global Non-Animal Alternative Testing Market Expected to Surpass $29,390.20 Million, Rising at 13.0% CAGR from 2021 to 2030 [290-Pages] | Research Dive
March 30, 2022 09:15 ET
|
Research Dive
New York, USA, March 30, 2022 (GLOBE NEWSWIRE) -- A new report on the global non-animal alternative testing market has been added by Research Dive to its repository. According to the report, the...